$AQST insider trading
Over the last 12 months, Aquestive Therapeutics insiders reported no purchases and 17 sales totaling $3.4M across SEC Form 4 filings. 59% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3.4M 17 events
- Events · 12m
- 17 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 59% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Barber DanielPresident and CEO · O·D | ▼ Sale | 25,000 | $4.29 | $107K | -4.1% | plan |
| Jul 16, 2026 | Barber DanielPresident and CEO · O | ▼ Sale | 25,000 | $4.01 | $100K | -3.9% | plan · 2 tranches |
| Jun 23, 2026 | Krop JulieD | ▼ Sale | 25,000 | $5.02 | $125K | -100% | plan |
| Jun 15, 2026 | Barber DanielPresident and CEO · O | ▼ Sale | 25,000 | $4.16 | $104K | -3.8% | plan |
| Mar 10, 2026 | Boyd Peter E.Chief People Officer · O | ▼ Sale | 29,814 | $4.17 | $124K | -8.1% | — |
| Mar 10, 2026 | Barber DanielPresident and CEO · O | ▼ Sale | 180,677 | $4.17 | $754K | -15.2% | — |
| Mar 10, 2026 | BRAENDER LORI JChief Legal Officer · O | ▼ Sale | 40,102 | $4.17 | $167K | -8.3% | — |
| Mar 10, 2026 | Cioffi MelinaSVP, Regulatory Affairs · O | ▼ Sale | 25,311 | $4.17 | $106K | -8.4% | — |
| Mar 10, 2026 | TOTH A ERNEST JRChief Financial Officer · O | ▼ Sale | 58,254 | $4.17 | $243K | -13.4% | — |
| Mar 10, 2026 | Korczynski SherryChief Commercial Officer · O | ▼ Sale | 15,741 | $4.17 | $66K | -6.1% | — |
| Mar 10, 2026 | Jung CassieChief Operating Officer · O | ▼ Sale | 45,791 | $4.17 | $191K | -14.3% | — |
| Oct 15, 2025 | Jung CassieChief Operating Officer · O | ▼ Sale | 67,575 | $7.01 | $474K | -21.9% | plan |
| Oct 15, 2025 | Kraus Carl NChief Medical Officer · O | ▼ Sale | 20,272 | $7 | $142K | -6.7% | plan |
| Oct 15, 2025 | Boyd Peter E.See Remarks · O | ▼ Sale | 10,000 | $7 | $70K | -3.6% | plan |
| Sep 26, 2025 | Barber DanielPresident and CEO · O·D | ▼ Sale | 91,343 | $6.03 | $551K | -9% | plan |
| Sep 26, 2025 | Boyd Peter E.See Remarks · O | ▼ Sale | 10,000 | $6.3 | $63K | -3.5% | plan |
| Sep 19, 2025 | Barber DanielPresident and CEO · O·D | ▼ Sale | 400 | $6 | $2K | — | plan |
| Sep 5, 2025 | Boyd Peter E.See Remarks · O | ▼ Sale | 15,000 | $5.3 | $80K | -4.9% | plan |
| Sep 4, 2025 | Jung CassieChief Operating Officer · O | ▼ Sale | 62,180 | $5 | $311K | -18% | plan |
Every $AQST filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Aquestive Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AQST feed.